Our weekly market outlook, straight to your inbox.

Get the Schaeffer’s edge every Monday.

 

 
 
 
X

Analyst Upgrades: BioMarin, Digital Ally, and Marvell

Jun 18, 2015, 09:28 AM by Karee Venema
Analysts upwardly revised their ratings on BioMarin Pharmaceutical Inc. (BMRN), Digital Ally, Inc. (DGLY), and Marvell Technology Group Ltd. (MRVL)
Analysts are weighing in on drugmaker BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), surveillance specialist Digital Ally, Inc. (NASDAQ:DGLY), and semiconductor concern Marvell Technology Group Ltd. (NASDAQ:MRVL). Here's a quick roundup of today's bullish brokerage notes on BRMN, DGLY, and MRVL.

  • BMRN is up 7.2% in electronic trading, after receiving a number of upbeat analyst notes following reports the company's experimental dwarfism drug, BMN 111, showed promise in a mid-stage study. William Blair, for example, raised its price target to $140 from $126, saying it expects the treatment to be a breakout product for BioMarin Pharmaceutical Inc. SunTrust Robinson, meanwhile, boosted its target price by $19 to $170, explaining it projects global sales of roughly $700 million. On the charts, the stock has had a standout year -- up nearly 37% to trade at $123.60, hitting a late-March record high of $133.54 along the way. Option traders have been rolling the dice on more upside, too. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), speculators have bought to open 12.94 calls for every put over the past 10 days.

  • H.C. Wainwright initiated coverage on DGLY with a "buy" rating and a $24 price target, representing expected upside of 77% to last night's close at $13.56 -- and a trek into territory not seen since last September. As a result, the stock is up 8.7% ahead of the bell. Today's projected price move would be welcome for a security that's down almost 28% from its mid-May year-to-date high of $18.80. Plus, the shares are poised to topple the $14 mark -- an area that has contained DGLY for most of the past month. On the sentiment front, traders have taken the skeptical route. Specifically, a healthy 19.4% of Digital Ally, Inc.'s float is sold short.

  • Goldman Sachs raised its outlook on MRVL to "neutral" from "sell," removed the stock from its "America's Sell" list, and upped its price target to $14 -- sending the shares 1.4% higher in electronic trading. Technically speaking, MRVL has been on the mend since hitting a 2015 low of $13.05 on May 22, up 8% to trade at $14.10. Against this backdrop, analysts have been changing their skeptical tune, and currently 11 out of 25 maintain a "buy" or better rating on Marvell Technology Group Ltd. This growing optimism has been seen in the options pits, as well, where MRVL's 10-day ISE/CBOE/PHLX call/put volume ratio has jumped to 60.54 from 8.32 over the past two weeks. What's more, the current ratio ranks in the 92nd annual percentile, meaning long calls have been initiated over long puts at a near-annual-high clip.

Analyst Upgrades: BioMarin, Digital Ally, and Marvell

by Karee Venema | Jun 18, 2015
Analysts are weighing in on drugmaker BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), surveillance specialist Digital Ally, Inc. (NASDAQ:DGLY), and semiconductor concern Marvell Technology Group Ltd. (NASDAQ:MRVL). Here's a quick roundup of today's bullish brokerage notes on BRMN, DGLY, and MRVL.

  • BMRN is up 7.2% in electronic trading, after receiving a number of upbeat analyst notes following reports the company's experimental dwarfism drug, BMN 111, showed promise in a mid-stage study. William Blair, for example, raised its price target to $140 from $126, saying it expects the treatment to be a breakout product for BioMarin Pharmaceutical Inc. SunTrust Robinson, meanwhile, boosted its target price by $19 to $170, explaining it projects global sales of roughly $700 million. On the charts, the stock has had a standout year -- up nearly 37% to trade at $123.60, hitting a late-March record high of $133.54 along the way. Option traders have been rolling the dice on more upside, too. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), speculators have bought to open 12.94 calls for every put over the past 10 days.

  • H.C. Wainwright initiated coverage on DGLY with a "buy" rating and a $24 price target, representing expected upside of 77% to last night's close at $13.56 -- and a trek into territory not seen since last September. As a result, the stock is up 8.7% ahead of the bell. Today's projected price move would be welcome for a security that's down almost 28% from its mid-May year-to-date high of $18.80. Plus, the shares are poised to topple the $14 mark -- an area that has contained DGLY for most of the past month. On the sentiment front, traders have taken the skeptical route. Specifically, a healthy 19.4% of Digital Ally, Inc.'s float is sold short.

  • Goldman Sachs raised its outlook on MRVL to "neutral" from "sell," removed the stock from its "America's Sell" list, and upped its price target to $14 -- sending the shares 1.4% higher in electronic trading. Technically speaking, MRVL has been on the mend since hitting a 2015 low of $13.05 on May 22, up 8% to trade at $14.10. Against this backdrop, analysts have been changing their skeptical tune, and currently 11 out of 25 maintain a "buy" or better rating on Marvell Technology Group Ltd. This growing optimism has been seen in the options pits, as well, where MRVL's 10-day ISE/CBOE/PHLX call/put volume ratio has jumped to 60.54 from 8.32 over the past two weeks. What's more, the current ratio ranks in the 92nd annual percentile, meaning long calls have been initiated over long puts at a near-annual-high clip.

Analyst Upgrades: BioMarin, Digital Ally, and Marvell

by Karee Venema | Jun 18, 2015
Analysts are weighing in on drugmaker BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), surveillance specialist Digital Ally, Inc. (NASDAQ:DGLY), and semiconductor concern Marvell Technology Group Ltd. (NASDAQ:MRVL). Here's a quick roundup of today's bullish brokerage notes on BRMN, DGLY, and MRVL.

  • BMRN is up 7.2% in electronic trading, after receiving a number of upbeat analyst notes following reports the company's experimental dwarfism drug, BMN 111, showed promise in a mid-stage study. William Blair, for example, raised its price target to $140 from $126, saying it expects the treatment to be a breakout product for BioMarin Pharmaceutical Inc. SunTrust Robinson, meanwhile, boosted its target price by $19 to $170, explaining it projects global sales of roughly $700 million. On the charts, the stock has had a standout year -- up nearly 37% to trade at $123.60, hitting a late-March record high of $133.54 along the way. Option traders have been rolling the dice on more upside, too. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), speculators have bought to open 12.94 calls for every put over the past 10 days.

  • H.C. Wainwright initiated coverage on DGLY with a "buy" rating and a $24 price target, representing expected upside of 77% to last night's close at $13.56 -- and a trek into territory not seen since last September. As a result, the stock is up 8.7% ahead of the bell. Today's projected price move would be welcome for a security that's down almost 28% from its mid-May year-to-date high of $18.80. Plus, the shares are poised to topple the $14 mark -- an area that has contained DGLY for most of the past month. On the sentiment front, traders have taken the skeptical route. Specifically, a healthy 19.4% of Digital Ally, Inc.'s float is sold short.

  • Goldman Sachs raised its outlook on MRVL to "neutral" from "sell," removed the stock from its "America's Sell" list, and upped its price target to $14 -- sending the shares 1.4% higher in electronic trading. Technically speaking, MRVL has been on the mend since hitting a 2015 low of $13.05 on May 22, up 8% to trade at $14.10. Against this backdrop, analysts have been changing their skeptical tune, and currently 11 out of 25 maintain a "buy" or better rating on Marvell Technology Group Ltd. This growing optimism has been seen in the options pits, as well, where MRVL's 10-day ISE/CBOE/PHLX call/put volume ratio has jumped to 60.54 from 8.32 over the past two weeks. What's more, the current ratio ranks in the 92nd annual percentile, meaning long calls have been initiated over long puts at a near-annual-high clip.
  

ABOUTus


Schaeffer's Investment Research, Inc. has been providing stock market publications, market recommendation services and stock option education since its inception in 1981 by founder and CEO, Bernie Schaeffer.  Headquartered in Cincinnati, OH, Schaeffer's Investment Research has become a leading and trusted source of research and analysis for individual investors and major financial media outlets.

TRADINGpublications


|FROM THE TOP
by bernie schaeffer
Because today's investor is aware of the benefits of options trading, options investing is shifting to mainstream popularity, Bernie Schaeffer, author of The Option Advisor, continues to provide accessible, sophisticated analysis and research of options trading for every investor in his weekly and monthly columns.

Analyst Upgrades: BioMarin, Digital Ally, and Marvell

by Karee Venema | Jun 18, 2015
Analysts are weighing in on drugmaker BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), surveillance specialist Digital Ally, Inc. (NASDAQ:DGLY), and semiconductor concern Marvell Technology Group Ltd. (NASDAQ:MRVL). Here's a quick roundup of today's bullish brokerage notes on BRMN, DGLY, and MRVL.

  • BMRN is up 7.2% in electronic trading, after receiving a number of upbeat analyst notes following reports the company's experimental dwarfism drug, BMN 111, showed promise in a mid-stage study. William Blair, for example, raised its price target to $140 from $126, saying it expects the treatment to be a breakout product for BioMarin Pharmaceutical Inc. SunTrust Robinson, meanwhile, boosted its target price by $19 to $170, explaining it projects global sales of roughly $700 million. On the charts, the stock has had a standout year -- up nearly 37% to trade at $123.60, hitting a late-March record high of $133.54 along the way. Option traders have been rolling the dice on more upside, too. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), speculators have bought to open 12.94 calls for every put over the past 10 days.

  • H.C. Wainwright initiated coverage on DGLY with a "buy" rating and a $24 price target, representing expected upside of 77% to last night's close at $13.56 -- and a trek into territory not seen since last September. As a result, the stock is up 8.7% ahead of the bell. Today's projected price move would be welcome for a security that's down almost 28% from its mid-May year-to-date high of $18.80. Plus, the shares are poised to topple the $14 mark -- an area that has contained DGLY for most of the past month. On the sentiment front, traders have taken the skeptical route. Specifically, a healthy 19.4% of Digital Ally, Inc.'s float is sold short.

  • Goldman Sachs raised its outlook on MRVL to "neutral" from "sell," removed the stock from its "America's Sell" list, and upped its price target to $14 -- sending the shares 1.4% higher in electronic trading. Technically speaking, MRVL has been on the mend since hitting a 2015 low of $13.05 on May 22, up 8% to trade at $14.10. Against this backdrop, analysts have been changing their skeptical tune, and currently 11 out of 25 maintain a "buy" or better rating on Marvell Technology Group Ltd. This growing optimism has been seen in the options pits, as well, where MRVL's 10-day ISE/CBOE/PHLX call/put volume ratio has jumped to 60.54 from 8.32 over the past two weeks. What's more, the current ratio ranks in the 92nd annual percentile, meaning long calls have been initiated over long puts at a near-annual-high clip.
From The Top

Analyst Upgrades: BioMarin, Digital Ally, and Marvell

by Karee Venema | Jun 18, 2015
Analysts are weighing in on drugmaker BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), surveillance specialist Digital Ally, Inc. (NASDAQ:DGLY), and semiconductor concern Marvell Technology Group Ltd. (NASDAQ:MRVL). Here's a quick roundup of today's bullish brokerage notes on BRMN, DGLY, and MRVL.

  • BMRN is up 7.2% in electronic trading, after receiving a number of upbeat analyst notes following reports the company's experimental dwarfism drug, BMN 111, showed promise in a mid-stage study. William Blair, for example, raised its price target to $140 from $126, saying it expects the treatment to be a breakout product for BioMarin Pharmaceutical Inc. SunTrust Robinson, meanwhile, boosted its target price by $19 to $170, explaining it projects global sales of roughly $700 million. On the charts, the stock has had a standout year -- up nearly 37% to trade at $123.60, hitting a late-March record high of $133.54 along the way. Option traders have been rolling the dice on more upside, too. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), speculators have bought to open 12.94 calls for every put over the past 10 days.

  • H.C. Wainwright initiated coverage on DGLY with a "buy" rating and a $24 price target, representing expected upside of 77% to last night's close at $13.56 -- and a trek into territory not seen since last September. As a result, the stock is up 8.7% ahead of the bell. Today's projected price move would be welcome for a security that's down almost 28% from its mid-May year-to-date high of $18.80. Plus, the shares are poised to topple the $14 mark -- an area that has contained DGLY for most of the past month. On the sentiment front, traders have taken the skeptical route. Specifically, a healthy 19.4% of Digital Ally, Inc.'s float is sold short.

  • Goldman Sachs raised its outlook on MRVL to "neutral" from "sell," removed the stock from its "America's Sell" list, and upped its price target to $14 -- sending the shares 1.4% higher in electronic trading. Technically speaking, MRVL has been on the mend since hitting a 2015 low of $13.05 on May 22, up 8% to trade at $14.10. Against this backdrop, analysts have been changing their skeptical tune, and currently 11 out of 25 maintain a "buy" or better rating on Marvell Technology Group Ltd. This growing optimism has been seen in the options pits, as well, where MRVL's 10-day ISE/CBOE/PHLX call/put volume ratio has jumped to 60.54 from 8.32 over the past two weeks. What's more, the current ratio ranks in the 92nd annual percentile, meaning long calls have been initiated over long puts at a near-annual-high clip.
|MONDAY MORNING OUTLOOK
by todd salamone
Todd Salamone is the Senior VP of Research and author of the Monday Morning Outlook. To receive your weekly column, subscribe to Monday Morning Outlook.

Analyst Upgrades: BioMarin, Digital Ally, and Marvell

by Karee Venema | Jun 18, 2015
Analysts are weighing in on drugmaker BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), surveillance specialist Digital Ally, Inc. (NASDAQ:DGLY), and semiconductor concern Marvell Technology Group Ltd. (NASDAQ:MRVL). Here's a quick roundup of today's bullish brokerage notes on BRMN, DGLY, and MRVL.

  • BMRN is up 7.2% in electronic trading, after receiving a number of upbeat analyst notes following reports the company's experimental dwarfism drug, BMN 111, showed promise in a mid-stage study. William Blair, for example, raised its price target to $140 from $126, saying it expects the treatment to be a breakout product for BioMarin Pharmaceutical Inc. SunTrust Robinson, meanwhile, boosted its target price by $19 to $170, explaining it projects global sales of roughly $700 million. On the charts, the stock has had a standout year -- up nearly 37% to trade at $123.60, hitting a late-March record high of $133.54 along the way. Option traders have been rolling the dice on more upside, too. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), speculators have bought to open 12.94 calls for every put over the past 10 days.

  • H.C. Wainwright initiated coverage on DGLY with a "buy" rating and a $24 price target, representing expected upside of 77% to last night's close at $13.56 -- and a trek into territory not seen since last September. As a result, the stock is up 8.7% ahead of the bell. Today's projected price move would be welcome for a security that's down almost 28% from its mid-May year-to-date high of $18.80. Plus, the shares are poised to topple the $14 mark -- an area that has contained DGLY for most of the past month. On the sentiment front, traders have taken the skeptical route. Specifically, a healthy 19.4% of Digital Ally, Inc.'s float is sold short.

  • Goldman Sachs raised its outlook on MRVL to "neutral" from "sell," removed the stock from its "America's Sell" list, and upped its price target to $14 -- sending the shares 1.4% higher in electronic trading. Technically speaking, MRVL has been on the mend since hitting a 2015 low of $13.05 on May 22, up 8% to trade at $14.10. Against this backdrop, analysts have been changing their skeptical tune, and currently 11 out of 25 maintain a "buy" or better rating on Marvell Technology Group Ltd. This growing optimism has been seen in the options pits, as well, where MRVL's 10-day ISE/CBOE/PHLX call/put volume ratio has jumped to 60.54 from 8.32 over the past two weeks. What's more, the current ratio ranks in the 92nd annual percentile, meaning long calls have been initiated over long puts at a near-annual-high clip.
|INDICATOR OF THE WEEK
by rocky white
Rocky White is a quantitative analyst at Schaeffer’s Research and author of Indicator of the Week. To get more tips on options indicators, subscribe to any of our free publications.

Analyst Upgrades: BioMarin, Digital Ally, and Marvell

by Karee Venema | Jun 18, 2015
Analysts are weighing in on drugmaker BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), surveillance specialist Digital Ally, Inc. (NASDAQ:DGLY), and semiconductor concern Marvell Technology Group Ltd. (NASDAQ:MRVL). Here's a quick roundup of today's bullish brokerage notes on BRMN, DGLY, and MRVL.

  • BMRN is up 7.2% in electronic trading, after receiving a number of upbeat analyst notes following reports the company's experimental dwarfism drug, BMN 111, showed promise in a mid-stage study. William Blair, for example, raised its price target to $140 from $126, saying it expects the treatment to be a breakout product for BioMarin Pharmaceutical Inc. SunTrust Robinson, meanwhile, boosted its target price by $19 to $170, explaining it projects global sales of roughly $700 million. On the charts, the stock has had a standout year -- up nearly 37% to trade at $123.60, hitting a late-March record high of $133.54 along the way. Option traders have been rolling the dice on more upside, too. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), speculators have bought to open 12.94 calls for every put over the past 10 days.

  • H.C. Wainwright initiated coverage on DGLY with a "buy" rating and a $24 price target, representing expected upside of 77% to last night's close at $13.56 -- and a trek into territory not seen since last September. As a result, the stock is up 8.7% ahead of the bell. Today's projected price move would be welcome for a security that's down almost 28% from its mid-May year-to-date high of $18.80. Plus, the shares are poised to topple the $14 mark -- an area that has contained DGLY for most of the past month. On the sentiment front, traders have taken the skeptical route. Specifically, a healthy 19.4% of Digital Ally, Inc.'s float is sold short.

  • Goldman Sachs raised its outlook on MRVL to "neutral" from "sell," removed the stock from its "America's Sell" list, and upped its price target to $14 -- sending the shares 1.4% higher in electronic trading. Technically speaking, MRVL has been on the mend since hitting a 2015 low of $13.05 on May 22, up 8% to trade at $14.10. Against this backdrop, analysts have been changing their skeptical tune, and currently 11 out of 25 maintain a "buy" or better rating on Marvell Technology Group Ltd. This growing optimism has been seen in the options pits, as well, where MRVL's 10-day ISE/CBOE/PHLX call/put volume ratio has jumped to 60.54 from 8.32 over the past two weeks. What's more, the current ratio ranks in the 92nd annual percentile, meaning long calls have been initiated over long puts at a near-annual-high clip.
Weekly Publications

Analyst Upgrades: BioMarin, Digital Ally, and Marvell

by Karee Venema | Jun 18, 2015
Analysts are weighing in on drugmaker BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), surveillance specialist Digital Ally, Inc. (NASDAQ:DGLY), and semiconductor concern Marvell Technology Group Ltd. (NASDAQ:MRVL). Here's a quick roundup of today's bullish brokerage notes on BRMN, DGLY, and MRVL.

  • BMRN is up 7.2% in electronic trading, after receiving a number of upbeat analyst notes following reports the company's experimental dwarfism drug, BMN 111, showed promise in a mid-stage study. William Blair, for example, raised its price target to $140 from $126, saying it expects the treatment to be a breakout product for BioMarin Pharmaceutical Inc. SunTrust Robinson, meanwhile, boosted its target price by $19 to $170, explaining it projects global sales of roughly $700 million. On the charts, the stock has had a standout year -- up nearly 37% to trade at $123.60, hitting a late-March record high of $133.54 along the way. Option traders have been rolling the dice on more upside, too. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), speculators have bought to open 12.94 calls for every put over the past 10 days.

  • H.C. Wainwright initiated coverage on DGLY with a "buy" rating and a $24 price target, representing expected upside of 77% to last night's close at $13.56 -- and a trek into territory not seen since last September. As a result, the stock is up 8.7% ahead of the bell. Today's projected price move would be welcome for a security that's down almost 28% from its mid-May year-to-date high of $18.80. Plus, the shares are poised to topple the $14 mark -- an area that has contained DGLY for most of the past month. On the sentiment front, traders have taken the skeptical route. Specifically, a healthy 19.4% of Digital Ally, Inc.'s float is sold short.

  • Goldman Sachs raised its outlook on MRVL to "neutral" from "sell," removed the stock from its "America's Sell" list, and upped its price target to $14 -- sending the shares 1.4% higher in electronic trading. Technically speaking, MRVL has been on the mend since hitting a 2015 low of $13.05 on May 22, up 8% to trade at $14.10. Against this backdrop, analysts have been changing their skeptical tune, and currently 11 out of 25 maintain a "buy" or better rating on Marvell Technology Group Ltd. This growing optimism has been seen in the options pits, as well, where MRVL's 10-day ISE/CBOE/PHLX call/put volume ratio has jumped to 60.54 from 8.32 over the past two weeks. What's more, the current ratio ranks in the 92nd annual percentile, meaning long calls have been initiated over long puts at a near-annual-high clip.

TRADING SERVICES | FEATUREDproducts


By E.W. from Kentucky
I have tried many different programs and services in the past with mix results. Stop your search here. Schaeffer's Investment Research is bottom line the most professional, experienced, and confidence building investment research firm. After trying an initial package I spoke with my account manager, Nathane Sharp, who helped me tailor my trading style to the right package. His professionalism and experienced approach matched me perfectly. The track record speaks for itself and the money back guarantee sells you. I have found my investment firm for the rest of my trading career.
Options trading made simple.
Schaeffer's Investment Research, Inc. is dedicated to providing subscribers advantages in options trading and investing.  Our independent market research services create profitable opportunities for investors at every level.
FREE NEWS & ALERTS

Get the best of Schaeffer's financial market news every morning directly to your inbox.

Find Out How

TRENDINGnews


Analyst Upgrades: BioMarin, Digital Ally, and Marvell

by Karee Venema | Jun 18, 2015
Analysts are weighing in on drugmaker BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), surveillance specialist Digital Ally, Inc. (NASDAQ:DGLY), and semiconductor concern Marvell Technology Group Ltd. (NASDAQ:MRVL). Here's a quick roundup of today's bullish brokerage notes on BRMN, DGLY, and MRVL.

  • BMRN is up 7.2% in electronic trading, after receiving a number of upbeat analyst notes following reports the company's experimental dwarfism drug, BMN 111, showed promise in a mid-stage study. William Blair, for example, raised its price target to $140 from $126, saying it expects the treatment to be a breakout product for BioMarin Pharmaceutical Inc. SunTrust Robinson, meanwhile, boosted its target price by $19 to $170, explaining it projects global sales of roughly $700 million. On the charts, the stock has had a standout year -- up nearly 37% to trade at $123.60, hitting a late-March record high of $133.54 along the way. Option traders have been rolling the dice on more upside, too. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), speculators have bought to open 12.94 calls for every put over the past 10 days.

  • H.C. Wainwright initiated coverage on DGLY with a "buy" rating and a $24 price target, representing expected upside of 77% to last night's close at $13.56 -- and a trek into territory not seen since last September. As a result, the stock is up 8.7% ahead of the bell. Today's projected price move would be welcome for a security that's down almost 28% from its mid-May year-to-date high of $18.80. Plus, the shares are poised to topple the $14 mark -- an area that has contained DGLY for most of the past month. On the sentiment front, traders have taken the skeptical route. Specifically, a healthy 19.4% of Digital Ally, Inc.'s float is sold short.

  • Goldman Sachs raised its outlook on MRVL to "neutral" from "sell," removed the stock from its "America's Sell" list, and upped its price target to $14 -- sending the shares 1.4% higher in electronic trading. Technically speaking, MRVL has been on the mend since hitting a 2015 low of $13.05 on May 22, up 8% to trade at $14.10. Against this backdrop, analysts have been changing their skeptical tune, and currently 11 out of 25 maintain a "buy" or better rating on Marvell Technology Group Ltd. This growing optimism has been seen in the options pits, as well, where MRVL's 10-day ISE/CBOE/PHLX call/put volume ratio has jumped to 60.54 from 8.32 over the past two weeks. What's more, the current ratio ranks in the 92nd annual percentile, meaning long calls have been initiated over long puts at a near-annual-high clip.

OPTIONSnews


Analyst Upgrades: BioMarin, Digital Ally, and Marvell

by Karee Venema | Jun 18, 2015
Analysts are weighing in on drugmaker BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), surveillance specialist Digital Ally, Inc. (NASDAQ:DGLY), and semiconductor concern Marvell Technology Group Ltd. (NASDAQ:MRVL). Here's a quick roundup of today's bullish brokerage notes on BRMN, DGLY, and MRVL.

  • BMRN is up 7.2% in electronic trading, after receiving a number of upbeat analyst notes following reports the company's experimental dwarfism drug, BMN 111, showed promise in a mid-stage study. William Blair, for example, raised its price target to $140 from $126, saying it expects the treatment to be a breakout product for BioMarin Pharmaceutical Inc. SunTrust Robinson, meanwhile, boosted its target price by $19 to $170, explaining it projects global sales of roughly $700 million. On the charts, the stock has had a standout year -- up nearly 37% to trade at $123.60, hitting a late-March record high of $133.54 along the way. Option traders have been rolling the dice on more upside, too. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), speculators have bought to open 12.94 calls for every put over the past 10 days.

  • H.C. Wainwright initiated coverage on DGLY with a "buy" rating and a $24 price target, representing expected upside of 77% to last night's close at $13.56 -- and a trek into territory not seen since last September. As a result, the stock is up 8.7% ahead of the bell. Today's projected price move would be welcome for a security that's down almost 28% from its mid-May year-to-date high of $18.80. Plus, the shares are poised to topple the $14 mark -- an area that has contained DGLY for most of the past month. On the sentiment front, traders have taken the skeptical route. Specifically, a healthy 19.4% of Digital Ally, Inc.'s float is sold short.

  • Goldman Sachs raised its outlook on MRVL to "neutral" from "sell," removed the stock from its "America's Sell" list, and upped its price target to $14 -- sending the shares 1.4% higher in electronic trading. Technically speaking, MRVL has been on the mend since hitting a 2015 low of $13.05 on May 22, up 8% to trade at $14.10. Against this backdrop, analysts have been changing their skeptical tune, and currently 11 out of 25 maintain a "buy" or better rating on Marvell Technology Group Ltd. This growing optimism has been seen in the options pits, as well, where MRVL's 10-day ISE/CBOE/PHLX call/put volume ratio has jumped to 60.54 from 8.32 over the past two weeks. What's more, the current ratio ranks in the 92nd annual percentile, meaning long calls have been initiated over long puts at a near-annual-high clip.

EDITOR'Spicks


Analyst Upgrades: BioMarin, Digital Ally, and Marvell

by Karee Venema | Jun 18, 2015
Analysts are weighing in on drugmaker BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), surveillance specialist Digital Ally, Inc. (NASDAQ:DGLY), and semiconductor concern Marvell Technology Group Ltd. (NASDAQ:MRVL). Here's a quick roundup of today's bullish brokerage notes on BRMN, DGLY, and MRVL.

  • BMRN is up 7.2% in electronic trading, after receiving a number of upbeat analyst notes following reports the company's experimental dwarfism drug, BMN 111, showed promise in a mid-stage study. William Blair, for example, raised its price target to $140 from $126, saying it expects the treatment to be a breakout product for BioMarin Pharmaceutical Inc. SunTrust Robinson, meanwhile, boosted its target price by $19 to $170, explaining it projects global sales of roughly $700 million. On the charts, the stock has had a standout year -- up nearly 37% to trade at $123.60, hitting a late-March record high of $133.54 along the way. Option traders have been rolling the dice on more upside, too. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), speculators have bought to open 12.94 calls for every put over the past 10 days.

  • H.C. Wainwright initiated coverage on DGLY with a "buy" rating and a $24 price target, representing expected upside of 77% to last night's close at $13.56 -- and a trek into territory not seen since last September. As a result, the stock is up 8.7% ahead of the bell. Today's projected price move would be welcome for a security that's down almost 28% from its mid-May year-to-date high of $18.80. Plus, the shares are poised to topple the $14 mark -- an area that has contained DGLY for most of the past month. On the sentiment front, traders have taken the skeptical route. Specifically, a healthy 19.4% of Digital Ally, Inc.'s float is sold short.

  • Goldman Sachs raised its outlook on MRVL to "neutral" from "sell," removed the stock from its "America's Sell" list, and upped its price target to $14 -- sending the shares 1.4% higher in electronic trading. Technically speaking, MRVL has been on the mend since hitting a 2015 low of $13.05 on May 22, up 8% to trade at $14.10. Against this backdrop, analysts have been changing their skeptical tune, and currently 11 out of 25 maintain a "buy" or better rating on Marvell Technology Group Ltd. This growing optimism has been seen in the options pits, as well, where MRVL's 10-day ISE/CBOE/PHLX call/put volume ratio has jumped to 60.54 from 8.32 over the past two weeks. What's more, the current ratio ranks in the 92nd annual percentile, meaning long calls have been initiated over long puts at a near-annual-high clip.

ANALYSTupdates


Analyst Upgrades: BioMarin, Digital Ally, and Marvell

by Karee Venema | Jun 18, 2015
Analysts are weighing in on drugmaker BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), surveillance specialist Digital Ally, Inc. (NASDAQ:DGLY), and semiconductor concern Marvell Technology Group Ltd. (NASDAQ:MRVL). Here's a quick roundup of today's bullish brokerage notes on BRMN, DGLY, and MRVL.

  • BMRN is up 7.2% in electronic trading, after receiving a number of upbeat analyst notes following reports the company's experimental dwarfism drug, BMN 111, showed promise in a mid-stage study. William Blair, for example, raised its price target to $140 from $126, saying it expects the treatment to be a breakout product for BioMarin Pharmaceutical Inc. SunTrust Robinson, meanwhile, boosted its target price by $19 to $170, explaining it projects global sales of roughly $700 million. On the charts, the stock has had a standout year -- up nearly 37% to trade at $123.60, hitting a late-March record high of $133.54 along the way. Option traders have been rolling the dice on more upside, too. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), speculators have bought to open 12.94 calls for every put over the past 10 days.

  • H.C. Wainwright initiated coverage on DGLY with a "buy" rating and a $24 price target, representing expected upside of 77% to last night's close at $13.56 -- and a trek into territory not seen since last September. As a result, the stock is up 8.7% ahead of the bell. Today's projected price move would be welcome for a security that's down almost 28% from its mid-May year-to-date high of $18.80. Plus, the shares are poised to topple the $14 mark -- an area that has contained DGLY for most of the past month. On the sentiment front, traders have taken the skeptical route. Specifically, a healthy 19.4% of Digital Ally, Inc.'s float is sold short.

  • Goldman Sachs raised its outlook on MRVL to "neutral" from "sell," removed the stock from its "America's Sell" list, and upped its price target to $14 -- sending the shares 1.4% higher in electronic trading. Technically speaking, MRVL has been on the mend since hitting a 2015 low of $13.05 on May 22, up 8% to trade at $14.10. Against this backdrop, analysts have been changing their skeptical tune, and currently 11 out of 25 maintain a "buy" or better rating on Marvell Technology Group Ltd. This growing optimism has been seen in the options pits, as well, where MRVL's 10-day ISE/CBOE/PHLX call/put volume ratio has jumped to 60.54 from 8.32 over the past two weeks. What's more, the current ratio ranks in the 92nd annual percentile, meaning long calls have been initiated over long puts at a near-annual-high clip.

Partnercenter


OURfans